Nisha Bhatt

About Nisha Bhatt

I’m a physician-executive and double board-certified internist and nephrologist with over a decade of progressive leadership in U.S. and global Medical Affairs, with deep expertise across nephrology, pulmonology, hematology, immunology, and rare diseases.I’ve led the successful launch and lifecycle strategy for multiple blockbuster and first-in-class therapies—driving over $1.5B in cumulative revenue across U.S, EU, Japan, and China markets. My experience spans 5 global launches and multiple label expansions, including belimumab, daprodustat, and etelcalcetide, where I aligned evidence generation, regulatory strategy, and medical-commercial integration to accelerate access and adoption.At GSK, I scaled a global medical team, achieved launch readiness in 10+ markets in under 18 months, and led global medical strategic preparation for both FDA AdComm and EMA CHMP engagements. At Amgen, I spearheaded the U.S. launch of etelcalcetide, contributing to $630M+ in cumulative sales and 88% YoY growth, while executing a targeted RWE strategy that increased adoption by 25%.I bring a track record of building high-performing, cross-functional teams and engaging external stakeholders to drive scientific leadership and market impact. I’ve chaired global publication strategies producing 35+ manuscripts, expanded KOL networks by over 40%, and supported BD/in-licensing efforts across nephrology and immunology.Grounded in science, strategy, and a passion for improving patient outcomes, I bring both the strategic lens and executional discipline required to lead in today’s complex healthcare landscape. I’m now exploring new executive opportunities where I can apply my experience to shape medical strategy, drive launch excellence, and improve access to innovative therapies.

Experience

1. Global Medical Affairs Life Cycle Innovation - Immunology & Pulmonology

   GSK

   Jan 2024 — Present · Philadelphia, PA, US

   Leading global lifecycle strategy for belimumab in CTD-ILD and SSc-ILD, targeting $500M+ in incremental revenueAligning ILD strategy across therapeutic overlaps with cystic fibrosis to support CF-adjacent market readinessDriving cross-regional evidence and communication alignment for HTA and payer strategy across 20+ countriesExpanded KOL engagement by 40% and boosted HCP engagement at scientific forums by 30%Facilitating launch readiness via seamless collaboration with clinical, commercial, and market access teams

Education

• Tufts University

  Doctor of Medicine (MD), Focus on Health Care administration

  2000 — 2004

• Rutgers University

  Bachelor of Science (BS), Finance, General

  1996 — 2000

• Joan & Sanford I. Weill Medical College of Cornell University

  Clinical Research Associates Degree, Clinical Research Education

  2007 — 2007

• Harvard University

  Nephrology Fellow-Beth Israel Deaconess/Joslin Diabetes Center, Nephrology

  2008 — 2010

Skills

• Hospitals
• Clinical Research
• Ehr
• Clinical Trials
• Patient Safety
• Healthcare Management
• Inpatient
• Public Health
• Medical Education
• Healthcare
• Nephrology
• Internal Medicine
• Medicine
• Physicians
• Healthcare Information Technology
• Utilization Management
• Physician Relations
• Emr
• Strategic Planning